ArticleJournal of inflammation research2026
Dihydromyricetin Modulates Neuropathic Pain and Depression: A Correlation with Hippocampal Vascular Endothelial Growth Factor in Mice.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neuropathic pain (NP) is a multidisciplinary problem of medicine, psychology, sociology and economics. The emotional disorders caused by neuropathic pain are seriously underestimated. The dynamic interaction between the NP and emotional disorders greatly increasing the difficulty in clinical treatment, highlighting the importance of finding an effective treatment for neuropathic pain combined with depression. Dihydromyricetin (DHM) has been shown to be effective in improving neurological diseases due to its potent anti-inflammatory and neuroprotective effects. Methods: In this study, through network pharmacology and bioinformatics, the potential targets and signaling pathways of DHM in the treatment of neuropathic pain (NP) and depression (DP) comorbidities were predicted. Further animal experiments utilized the spared nerve injury (SNI) model in mice. Mice received daily intraperitoneal injections of DHM (20 mg kg Results: VEGFA was found to have the high "degree" value after ranking by target correlation based on the analysis from network pharmacology. SNI model evoked persistent the pain and depressive-like behavior that were paralleled by marked hippocampal down-regulation of VEGFA/VEGFR2 and a concomitant surge in IL-1β and TNF-α. However, the pain and depressive-like behavior can be relieved by DHM treatment. Both VEGFA and VEGFR2 were up-regulated in the hippocampus, and the changes of IL-1β and TNF-α were improved after DHM treatment. Discussion: This study elucidates that DHM alleviates neuropathic pain and depressive-like behavior, potentially be related to the upregulation of the VEGFA/VEGFR2 signaling pathway and subsequent attenuation of neuroinflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.